Cancer Medicine (Oct 2019)
Adjuvant chemotherapy versus chemoradiation in high‐risk pancreatic adenocarcinoma: A propensity score‐matched analysis
Abstract
Abstract Purpose The American Society of Clinical Oncology guidelines recommend adjuvant chemoradiation (ACR) for margin‐positive (R1) and/or node‐positive (N+) pancreatic cancers. Our goal was to investigate if there is evidence of superiority of adjuvant chemoradiation (ACR) over adjuvant chemotherapy (AC). Methods We utilized data from the National Cancer Database (NCDB) for N+ and/or R1 pancreatic adenocarcinoma patients diagnosed from 2004 to 2012 who underwent ACR or AC. Patients who received neoadjuvant radiation, no adjuvant treatment, or adjuvant radiation alone were excluded. Propensity score nearest‐neighbor 1:1 matching (PSM) was performed between ACR and AC groups based on age, sex, race, insurance, year of diagnosis, comorbidities, tumor site and size, T‐stage, nodal status, margin status, grade, and treatment facility. Primary outcome was overall survival (OS). Results A total of 8297 patients were eligible. After PSM, two well‐balanced groups of 3244 patients each were analyzed. ACR resulted in superior OS compared with AC alone (Hazard ratio [HR] 0.83, 95% CI 0.79‐0.87; median OS 22 vs 19 months, P < .0001). Subset analyses demonstrated OS benefit of ACR compared with AC in N+, R0 patients (HR: 0.82, 95% CI 0.77‐0.88; Median OS 24 vs 20 months, P < .001) as well as N+, R1 patients (HR: 0.77, 95% CI 0.68‐0.87; Median OS 17 vs 15 months, P < .001); but not in node‐negative, R1 patients (HR: 1.12, 95% CI 0.84‐1.48; Median OS 18 vs 22 months, P = .63). Conclusion The addition of radiation to AC was associated with a clinically small but meaningful increase in survival of patients undergoing curative‐intent pancreatic resections. This association was not evident in patients with microscopically positive margins but node‐negative disease and larger studies will be needed.
Keywords
